Publications by authors named "G Ossenkoppele"
Mutations in the Nucleophosmin-1 (NPM1) gene are among the most common molecular aberrations in acute myeloid leukemia (AML). Various studies have established mutant NPM1 (mNPM1) as a faithful molecular measurable residual disease (MRD) marker with prognostic significance. Assessment of prognostic mNPM1 is included in the European LeukemiaNet (ELN) recommendations on MRD detection in AML.
View Article and Find Full Text PDFArticle Synopsis
- Since 2017, combining targeted therapies with traditional chemotherapy has led to better outcomes for acute myeloid leukemia (AML) patients.
- A study of 5,359 AML patients over 20 years used data from the HARMONY Alliance to analyze treatment outcomes during four 5-year periods from 1997 to 2016.
- Results show significant improvements in 5-year survival rates and reduced 60-day mortality (from 13.0% to 4.7%), even across different genetic risk groups, indicating that the advancements in treatment have positively affected patient outcomes.
Article Synopsis
- Treatment outcomes for acute promyelocytic leukemia (APL) have significantly improved through targeted therapies like ATRA and arsenic trioxide, as confirmed by a study analyzing 1,438 newly diagnosed patients from 1999 to 2022.
- Among those treated, patients receiving the ATRA-ATO regimen demonstrated a higher 7-year overall survival rate (91%) compared to those on AIDA-like chemotherapy (81%), along with better event-free survival and lower relapse rates.
- The study highlights the ongoing issue of early death, particularly in older patients and those with high Sanz risk scores, suggesting a need for further examination and targeted interventions in these vulnerable groups.
The treatment of older patients with acute myeloid leukemia (AML) considered unfit for receiving intensive chemotherapy is challenging. Based on the hypothesis that addition of the broad tyrosine kinase inhibitor (TKI) midostaurin could improve the response to hypomethylating agents, irrespective of FLT3 gene mutational status, we conducted a randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to a 10-day schedule of decitabine in unfit (i.e.
View Article and Find Full Text PDFArticle Synopsis
- - The study focuses on older patients (over 60 years) with acute myeloid leukemia (AML) and aims to create a prognostic model to identify those who would benefit from intensive chemotherapy and stem cell transplantation.
- - Researchers analyzed data from 1,910 patients, using a random survival forest to evaluate clinical and genetic factors associated with overall survival, resulting in the identification of four distinct survival groups based on nine variables.
- - The newly developed AML60+ classification shows improved prognostic accuracy and indicates that intermediate- and very poor-risk patients may benefit from allogeneic hematopoietic cell transplantation, potentially guiding treatment decisions for older adults with AML.